DE69837393D1 - Stimulierung von hämatopoietischen zellen im vitro - Google Patents

Stimulierung von hämatopoietischen zellen im vitro

Info

Publication number
DE69837393D1
DE69837393D1 DE69837393T DE69837393T DE69837393D1 DE 69837393 D1 DE69837393 D1 DE 69837393D1 DE 69837393 T DE69837393 T DE 69837393T DE 69837393 T DE69837393 T DE 69837393T DE 69837393 D1 DE69837393 D1 DE 69837393D1
Authority
DE
Germany
Prior art keywords
hematopoietic cells
vitro
stimulation
methods
dpiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69837393T
Other languages
English (en)
Other versions
DE69837393T2 (de
Inventor
William Bachovchin
Barbara Wallner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Point Therapeutics Inc
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of DE69837393D1 publication Critical patent/DE69837393D1/de
Application granted granted Critical
Publication of DE69837393T2 publication Critical patent/DE69837393T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DE69837393T 1997-09-29 1998-09-29 Stimulierung von hämatopoietischen zellen im vitro Expired - Fee Related DE69837393T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6030697P 1997-09-29 1997-09-29
US60306P 1997-09-29
PCT/US1998/020343 WO1999016864A1 (en) 1997-09-29 1998-09-29 Stimulation of hematopoietic cells in vitro

Publications (2)

Publication Number Publication Date
DE69837393D1 true DE69837393D1 (de) 2007-05-03
DE69837393T2 DE69837393T2 (de) 2007-12-06

Family

ID=22028666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837393T Expired - Fee Related DE69837393T2 (de) 1997-09-29 1998-09-29 Stimulierung von hämatopoietischen zellen im vitro

Country Status (16)

Country Link
US (3) US6258597B1 (de)
EP (1) EP1019494B1 (de)
JP (2) JP2001518290A (de)
KR (1) KR100458403B1 (de)
CN (1) CN1163594C (de)
AT (1) ATE357509T1 (de)
AU (1) AU743996B2 (de)
BR (1) BR9813233A (de)
CA (1) CA2304206A1 (de)
DE (1) DE69837393T2 (de)
ES (1) ES2285785T3 (de)
IL (1) IL135068A (de)
NO (1) NO20001583L (de)
NZ (1) NZ503359A (de)
TR (1) TR200000815T2 (de)
WO (1) WO1999016864A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
US6300314B1 (en) 1998-05-04 2001-10-09 Point Therapeutics, Inc. Hematopoietic stimulation
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003512052A (ja) 1999-10-15 2003-04-02 アドバンスド セル テクノロジー、インコーポレイテッド 分化前駆細胞及び系統欠失胚性幹細胞の産生方法
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
EP2769715A3 (de) * 2001-11-26 2014-09-17 Trustees Of Tufts College Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
JP4771661B2 (ja) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
US7691967B2 (en) * 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20070172466A1 (en) * 2002-09-03 2007-07-26 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
EP1611233B1 (de) 2003-04-08 2016-01-06 Yeda Research And Development Co., Ltd. Stammzellen mit erhöhter empfindlichkeit für sdf-1 sowie methoden zu deren herstellung und verwendung
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
AU2005216970B2 (en) * 2004-02-23 2011-07-07 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US7883535B2 (en) * 2004-11-09 2011-02-08 Institut National D'optique Device and method for transmitting multiple optically-encoded stimulation signals to multiple cell locations
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1877547B1 (de) 2005-05-04 2012-08-08 Commonwealth Scientific and Industrial Research Organisation Selektion, kultivierung und erzeugung auf eine zellinie festgelegter hämatopoetischer stammzellen
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
NZ566799A (en) * 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PL2073810T3 (pl) * 2006-09-13 2012-01-31 Takeda Pharmaceuticals Co Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008094689A2 (en) * 2007-02-01 2008-08-07 Nephrogen, Llc Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
US20080195007A1 (en) * 2007-02-12 2008-08-14 Yury Podrazhansky Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20090297810A1 (en) * 2008-05-30 2009-12-03 Fiscus David M Polyethylene Films and Process for Production Thereof
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
EP4706663A3 (de) 2011-08-30 2026-05-20 Trustees Of Tufts College Fap-aktivierte proteasomhemmer zur behandlung fester tumore
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2594295A1 (de) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Nervenimplantat basierend auf einem kompaktierten, zellhaltigen Biomaterial
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
CN104998262B (zh) * 2014-04-21 2018-02-16 中国医学科学院放射医学研究所 Dpp4抑制剂在防治辐射诱导骨髓抑制药物中的应用
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR101715468B1 (ko) * 2015-03-31 2017-03-13 서울대학교산학협력단 활성화 b 세포를 이용한 항원 특이적 세포 독성 t 세포 제조 방법 및 그 용도
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
EP3763726A1 (de) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Verbindungen mit fibroblasten-aktivierendem proteinligand und deren verwendung
EP4050018A1 (de) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Verbindungen mit fibroblasten-aktivierendem proteinligand und deren verwendung
EP4274835A1 (de) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Verbindungen mit einem fibroblastenaktivierungsproteinliganden und verwendung davon
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE158109C (de)
US4318904A (en) 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4443609A (en) 1980-05-19 1984-04-17 Petrolite Corporation Tetrahydrothiazole phosphonic acids or esters thereof
DD158109A1 (de) 1981-04-10 1982-12-29 Gunter Fischer Verfahren zur hemmung der katalytischen aktivitaet von peptidhydrolasen
US4582821A (en) 1983-11-16 1986-04-15 E. I. Du Pont De Nemours And Company Inhibition of cyclic nucleotide independent protein kinases
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4636492A (en) 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US4652552A (en) 1984-09-10 1987-03-24 E. I. Du Pont De Nemours And Company Tetrapeptide methyl ketone inhibitors of viral proteases
US4644055A (en) 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
DD270382A1 (de) 1986-10-31 1989-07-26 Univ Halle Wittenberg Verfahren zur kolorimetrischen bestimmung von dipeptidylpeptidase iv mittels dipeptidhydraziden
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
WO1989006280A1 (en) 1988-01-04 1989-07-13 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
DE68924850T2 (de) 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
IL91307A0 (en) 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
DE3840452A1 (de) 1988-12-01 1990-06-07 Hoechst Ag (beta)-amino-boronsaeure-derivate
DE3842197A1 (de) 1988-12-15 1990-06-21 Hoechst Ag Rasch spaltbares substrat fuer die hiv-protease
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
DD296075A5 (de) 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
US4999082A (en) * 1989-09-14 1991-03-12 Akzo America Inc. Process for producing monocrystalline group II-IV or group III-V compounds and products thereof
DE4033062A1 (de) 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
EP0528858B1 (de) 1990-04-14 1997-01-22 New England Medical Center Hospitals, Inc. Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5378624A (en) 1990-04-23 1995-01-03 Cellpro, Incorporated Methods for removing ligands from a particle surface
WO1991017767A1 (en) 1990-05-21 1991-11-28 New England Medical Center Hospitals, Inc. Method of treating inhibition of dipeptidyl aminopeptidase type iv
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
JPH06504547A (ja) 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
EP0578745A1 (de) 1991-04-04 1994-01-19 The Upjohn Company Phosphorhaltige verbindungen als inhibitoren von retroviren
IE922316A1 (en) 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
WO1993005011A1 (en) 1991-08-29 1993-03-18 Sandoz Ltd. Novel immunosuppressants
CA2121369C (en) 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
WO1993016102A1 (en) 1992-02-06 1993-08-19 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
AU4794393A (en) * 1992-07-31 1994-03-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
EP0583536B1 (de) 1992-08-14 1997-03-05 The Procter & Gamble Company Alpha-aminoborsäurehaltige flüssige Waschmittel
WO1994009132A1 (en) 1992-08-21 1994-04-28 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
FR2701951B1 (fr) 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
HUT72735A (en) 1993-03-03 1996-05-28 Sandoz Ag Process for producing peptides inhibiting serine-proteaze enzymes and pharmaceutical compositions containing them
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
AU6773994A (en) 1993-04-23 1994-11-21 Cellpro, Incorporated Methods for enriching fetal progenitor cells from maternal blood
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
FR2707170A1 (fr) 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995011689A1 (en) 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
NL9400309A (nl) 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
US5890898A (en) * 1993-11-08 1999-04-06 Wada; Eric Minoru Infection control guard for dental air-water syringes
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
FR2719049B1 (fr) 1994-04-22 1996-06-14 Pasteur Institut Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules.
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
HUT77345A (hu) 1994-04-29 1998-03-30 Texas Biotechnology Corporation E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
DE4416963C1 (de) 1994-05-13 1995-07-13 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Diarylprolinolen
EP0764151A2 (de) * 1994-06-10 1997-03-26 Universitaire Instelling Antwerpen Reinigung von serine-protease und dessen synthetischen inhibitoren
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP2002515724A (ja) * 1995-06-01 2002-05-28 ダナ−ファーバー キャンサー インスティテュート インコーポレイテッド ヒト血清中に見出されたジペプチジルペプチダーゼｉｖ（ｃｄ２６）の新規形態、その抗体および利用法
ES2162081T3 (es) 1995-06-07 2001-12-16 Aastrom Biosciences Inc Aparato y procedimiento para el mantenimiento y crecimiento de celulas biologicas.
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
JP2001518290A (ja) * 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
WO1999028474A2 (en) 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
EP1052994A2 (de) * 1998-02-02 2000-11-22 Trustees Of Tufts College Verwendung von dipetidylpeptidasehemmer zur regulierung des glukosemetabolismus
EP1062222A1 (de) 1998-03-09 2000-12-27 Fondatech Benelux N.V. Serin-peptidase modulatoren
US6300314B1 (en) * 1998-05-04 2001-10-09 Point Therapeutics, Inc. Hematopoietic stimulation
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
AU765370B2 (en) * 1998-06-05 2003-09-18 Point Therapeutics, Inc. Cyclic boroproline compounds
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) * 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
CA2339537A1 (en) 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
HK1046846A1 (zh) 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
DE19926233C1 (de) * 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Verfahren zur Herstellung von Thiazolidin
DE60029230T2 (de) * 1999-09-10 2007-06-06 The University Of Sydney, Sydney Dipeptidyl-peptidasen
JP2003528135A (ja) 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
DE10025464A1 (de) 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
CA2411971A1 (en) 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases
CA2422889C (en) * 2000-10-27 2010-01-26 Probiodrug Ag Method for the treatment of neurological and neuropsychological disorders
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE10150203A1 (de) * 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) * 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030135023A1 (en) * 2001-06-27 2003-07-17 Hans-Ulrich Demuth Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
US20030125304A1 (en) * 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
JP4771661B2 (ja) 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
EP2769715A3 (de) * 2001-11-26 2014-09-17 Trustees Of Tufts College Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
ATE349435T1 (de) * 2002-02-28 2007-01-15 Prosidion Ltd Dpiv-inhibitoren auf glutaminbasis
US7691967B2 (en) 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US7238724B2 (en) * 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1622870A2 (de) 2003-05-05 2006-02-08 Prosidion Ltd. Glutaminylbasierte dp-iv-inhibitoren
WO2005071073A1 (en) 2004-01-09 2005-08-04 Point Therapeutics, Inc. Fap compositions and the use thereof for immunomodulation
AU2005216970B2 (en) 2004-02-23 2011-07-07 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
US7348346B2 (en) * 2004-03-08 2008-03-25 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050215603A1 (en) * 2004-03-08 2005-09-29 Irini Akritopoulou-Zanze Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
EP1745293A1 (de) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostika und therapeutika für mit dipeptidyl-peptidase 9 (dpp9) assoziierten krankheiten
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

Also Published As

Publication number Publication date
BR9813233A (pt) 2000-08-22
US6703238B2 (en) 2004-03-09
JP2006081554A (ja) 2006-03-30
CN1163594C (zh) 2004-08-25
US6258597B1 (en) 2001-07-10
ES2285785T3 (es) 2007-11-16
IL135068A0 (en) 2001-05-20
KR100458403B1 (ko) 2004-11-26
US20010018210A1 (en) 2001-08-30
WO1999016864A1 (en) 1999-04-08
CN1272136A (zh) 2000-11-01
EP1019494B1 (de) 2007-03-21
ATE357509T1 (de) 2007-04-15
AU743996B2 (en) 2002-02-14
TR200000815T2 (tr) 2000-12-21
KR20010030775A (ko) 2001-04-16
JP2001518290A (ja) 2001-10-16
JP4102403B2 (ja) 2008-06-18
EP1019494A1 (de) 2000-07-19
IL135068A (en) 2004-03-28
US20040152192A1 (en) 2004-08-05
US7276371B2 (en) 2007-10-02
NO20001583D0 (no) 2000-03-27
AU9588798A (en) 1999-04-23
DE69837393T2 (de) 2007-12-06
CA2304206A1 (en) 1999-04-08
NZ503359A (en) 2002-02-01
NO20001583L (no) 2000-05-29

Similar Documents

Publication Publication Date Title
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
GR3024181T3 (en) N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors.
NO975716L (no) Imidazolforbindelser
ES2054747T3 (es) Nuevos antidepresivos.
GB0209891D0 (en) Novel compounds
DE69736669D1 (de) Zelladhäsionsinhibitoren
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
NO992282L (no) Benzonaftyridiner som bronkialterapentika
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
ATE213952T1 (de) Freisetzung und mobilisierung hämatopoietischer zellen
EP1589998A4 (de) Verwendung von säuger-zytokin; verwandte reagenzien
DE69332770D1 (de) Sulfonylalkanoylaminohydroxyethylaminosulfamidsäuren verwendbar als retrovirale Proteasehemmer
AU632846B2 (en) Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
ATE228760T1 (de) Thrombininhibitoren
DE60334499D1 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ES2120506T3 (es) Nuevas amidas, sulfonamidas y sulfonamidas de piperidilo utilizadas como inhibidores de la biosintesis del colesterol.
MXPA02011558A (es) Inhibidores de mmp-2/mp-9 novedosos.
TR200402322T4 (tr) Triptaz inhibitörler
DK1244614T3 (da) Tryptase-inhibitorer
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
ES2158441T3 (es) Arilheterociclos con actividad herbicida.
MY106261A (en) Anti-inflammatory 1-heteroaryl oxindole-3-carboxamides.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee